에 대한 최신 뉴스 Illumina (NASDAQ:ILMN) 주식

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Analyst Color

Long Ideas

Health Care

Analyst Ratings

Tech

Trading Ideas

General

ILMN

NVDA

엔비디아(NASDAQ:NVDA)의 제품은 GPU와 게임에 국한되지 않는다. 이 기술 회사는 현재 헬스케어 인공지능 분야에서도 주목받고 있다. 월요일에 열린 J.P. 모건의 헬스케어 컨퍼런스에서 애널리스트 할란 서(Harlan Sur)는 엔비디아의 전략적 위치와 향후 성장의 주요 동력을 강조했다. 이것이 월스트리트와 병원들이 주목하고 있는 이유이다.

엔비디아가 의료 AI로 10억 달러의 매출을 겨냥: 다음 성장의 지평으로 거듭날까?

Equities

News

Markets

ETFs

ADPT

ARKG

ARKK

NTLA

RXRX

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:RXRX), 일루미나(NASDAQ:ILMN), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 클라우드플레어(NYSE:NET) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)의 주요 회사들에서 상당한 거래를 진행했다.

캐시 우드의 아크 인베스트, 인력의 4분의 1 이상을 해고한 인텔리아 테라퓨틱스에 투자

Education

주식 시장은 12월 마지막 거래일에 이익을 얻는 경향이 있다는 사실이 잘 입증되어 있습니다. 이는 &#34;산타 클로스 랠리&#34;로 알려진 현상이다. 이 낙관적인 시기는 역사적으로 투자자들에게 기쁨을 안겨주었으며, S&amp;P 500 지수가 지난 96년 중 64년에서 12월 24일부터 12월 31일 사이에 상승하여 평균 0.85%의 괜찮은 수익률을 기록했다. 이는 시즌액스(Seasonax)의 데이터에 따른 것이다.

산타 랠리: 연말 기간 동안 일관되게 우수한 성과를 보여주는 S&amp;P 500 주식 10종

Illumina Inc

Illumina Inc COM-WHEN ISSUED

On Tuesday, Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) raised its fourth-quarter revenues outlook to $1.10 billion, compared with a <a target="_blank" href="https://www.prnewswire.com/news-releases/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024-302295734.html" rel="noreferrer noopener">prior view</a> <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">of $1.07&nbsp;billion</a>. The street view also stands at $1.072 billion. The current outlook represents 1% growth year over year.
The company&#8217;s full-year revenue for 2024 is approximately&nbsp;expected to be $4.33 billion&nbsp;versus the analyst consensus estimate of $4.304 billion, down 2% year over year. It previously expected it to fall 3% year over year.
For the fourth quarter of 2024, the company expects adjusted diluted earnings per share in the range of approximately 91 cents to 93 cents versus the street view of 91 cents.
For the full year 2024, the adjusted diluted EPS is projected to be between $4.12 and $4.14, versus the analyst consensus estimate of $4.13 (prior view:&nbsp;$4.05 &#8211; $4.15&nbsp;).
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/01/42974739/wall-street-rebounds-as-producer-inflation-misses-estimates-tesla-gains-chinese-stocks-rally" rel="noreferrer noopener">Wall Street Rebounds As Producer Inflation Misses Estimates, Tesla Gains, Chinese Stocks Rally</a>
The company expects a non-GAAP operating margin of approximately 19.7% for the fourth quarter of 2024 and around 21.3% for the full year (prior view: 21% &#8211; 21.5%).
For 2024, the company expects cash flow from operations of around $1.21 billion and free cash flow of about $1.07 billion.
For fiscal year 2025, it forecasts low single-digit revenue growth in constant currency, with reported revenue between $4.28 billion and $4.4 billion, a non-GAAP operating margin of approximately 23%, and a 10% growth in non-GAAP diluted EPS.
Yesterday, Illumina announced a collaboration with NVIDIA Corporation to enhance technology platforms for analyzing and interpreting multiomic data.
This partnership aims to speed up progress in clinical research, genomics AI development, and drug discovery. By combining Illumina&#8217;s sequencing and informatics tools with NVIDIA&#8217;s AI technology, the partnership&nbsp;seeks to improve <a target="_blank" href="https://www.benzinga.com//node/42945242" rel="noreferrer noopener">drug discovery and clinical development.</a>
Price Action: ILMN shares are trading lower by 3.94% to $138.54 at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/42974082/nvidia-eyes-1-billion-in-healthcare-ai-revenue-next-growth-frontier" target="_blank" rel="noreferrer noopener">Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?</a></li>
</ul>
Photo via Shutterstock.

Guidance

Movers

Illumina Raises Q4 Revenue Outlook To $1.10 Billion, Exceeding Street Expectations; Sees Solid Margins

Illumina shares are trading lower after the company provided preliminary Q4 and FY24 financial results and FY25 guidance.

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January&nbsp;14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com.
Core Illumina
<ul>
<li>Revenue of approximately $1.10 billion for Q4 2024, up 1% from Q4 2023</li>
<li>Revenue of approximately $4.33 billion for 2024, down 2% from 2023 (and on a constant currency basis)</li>
<li>GAAP operating margin of approximately 16.7% for Q4 2024 and 34.2% for 2024</li>
<li>Non-GAAP operating margin of approximately 19.7% for Q4 2024 and 21.3% for 2024</li>
<li>GAAP diluted EPS of approximately $0.77 - $0.79 for Q4 2024 and $5.65 - $5.67 for 2024</li>
<li>Non-GAAP diluted EPS of approximately $0.91 - $0.93 for Q4 2024 and $4.12 - $4.14 for 2024</li>
<li>Cash flow provided by operations of approximately $1.21 billion and free cash flow (cash flow provided by operations less capital expenditures) of approximately $1.07 billion for 2024</li>
<li>For fiscal year 2025, expect constant currency revenue growth in the low single digits (reported revenue in the range of approximately $4.28 billion to $4.4 billion), non-GAAP operating margin of approximately 23%, and non-GAAP diluted EPS growth of approximately 10%</li>
</ul>
As previously announced, the company expects to report its full fourth quarter and fiscal year 2024&nbsp;results following the close of market on Thursday, February 6, 2025. The unaudited results in this press release are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment.

Earnings

Illumina Announces Preliminary Financials For Q4 2024 With $1.10B Revenue, 2024 Revenue At $4.33B, GAAP EPS $5.65-$5.67; Non-GAAP EPS $4.12-$4.14; Sees 2025 Revenue Outlook Of $4.28B-$4.4B, Non-GAAP Margin 23%, EPS Growth 10%

Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) products aren&#8217;t just about GPUs and gaming. The technology company is now making waves <a href="https://www.benzinga.com/topic/artificial-intelligence">in healthcare artificial intelligence</a>.
At J.P. Morgan's Healthcare Conference on Monday, analyst Harlan Sur emphasized Nvidia&#8217;s strategic positioning and highlighted key drivers for future growth. Here's why Wall Street and hospitals alike are paying attention.
<h2 class="wp-block-heading">AI Agents To The Rescue</h2>
With a looming shortage of up to 20 million healthcare workers, Nvidia is stepping in with AI-driven solutions like delivery robots and generative AI for clinical conversations. Sur noted the rising demand for such agentic AI solutions due to labor shortages, with Nvidia already partnering with firms like Intrivo and Abridge to deploy these technologies.
These &#8220;digital health agents&#8221; aren&#8217;t just futuristic toys—they&#8217;re becoming vital to filling critical workforce gaps. Partnerships with players like Intrivo and Abridge underscore the real-world traction Nvidia is gaining.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">Jensen Huang Said Quantum Computing Is 20 Years Away, But Nvidia Bets Big On Strategic Hiring</a>
<h2 class="wp-block-heading">Nvidia: Big Platforms, Bigger Ambitions</h2>
Nvidia's powerful datacenter platforms—Omniverse, Cosmos, and DGX Cloud—are pushing healthcare AI adoption to new heights. According to Sur, the flexibility Nvidia offers across on-premise, cloud-based, or hybrid models is helping drive enterprise adoption. 
With a projected $1 billion in annual recurring healthcare revenues by FY26, the company is tapping into a market worth hundreds of billions.
<h2 class="wp-block-heading">Nvidia&#8217;s Tech Meets Medicine</h2>
From drug discovery to robotics-assisted surgeries, Nvidia embeds AI across medical devices and hospital operations. Sur highlighted Nvidia&#8217;s use of Omniverse and Cosmos platforms for creating physics-aware virtual environments to train robots and develop medical technologies.
<h2 class="wp-block-heading">Genomics, Partnerships, Competitive Firepower</h2>
New collaborations with Iqvia Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) and Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) signal Nvidia's aggressive push to dominate healthcare AI. Sur noted these strategic partnerships as critical steps in Nvidia&#8217;s healthcare AI roadmap.
From drug discovery to genomic research, Nvidia aims to unlock breakthroughs that could reshape human health.
If Sur's projections hold, healthcare AI could be Nvidia's next billion-dollar play.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42967114/what-does-joe-bidens-last-minute-chip-export-restrictions-mean-for-nvidia-that-has-jensen-huang-led-ai-giant-up-in-arms">Joe Biden Vs. Jensen Huang: What White House&#8217;s New Chip Export Restrictions Mean For Nvidia That Has The AI Giant Up In Arms</a></li>
</ul>
Image: Shutterstock

Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?

Morgan Stanley analyst Tejas Savant maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and lowers the price target from $156 to $150.

Price Target

Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $150

Contracts

Illumina, NVIDIA To Collaborate To 'Decode Biology And Propel Precision Health;' Illumina Shares Spike Higher

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &amp; Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep&#x2122;, powered by SOMAmer&#xAE; technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis

Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades in five major companies on Friday: Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The RXRX Trade
Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) purchased a substantial 264,596 shares of&nbsp;Recursion Pharmaceuticals.
The value of this trade, calculated from the closing price of $6.88, is approximately $1.82 million. This move comes despite RXRX&#8217;s stock closing at a 5.23% decrease on Friday.
The ILMN Trade
Ark Invest&#8217;s Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF both bought shares of&nbsp;Illumina Inc.
ARKG acquired 4038 shares, while ARKK purchased 11425 shares. The combined value of these trades, calculated from the closing price of $136.69, is approximately $1.97 million.
This move was made despite Illumina's stock closing at a 2.14% decrease on Friday.
See Also: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">Bitcoin Supercycle Incoming, Says Economist, But There&#8217;s A Catch</a>
The NTLA Trade
Ark Invest&#8217;s Genomic Revolution ETF and ARK Innovation ETF both bought shares of&nbsp;Intellia Therapeutics.
ARKG acquired 41503 shares, while ARKK purchased 124799 shares.
The combined value of these trades, calculated from the closing price of $10.2, is approximately $1.46 million. This move was made despite NTLA&#8217;s stock closing at a 15.14% decrease on Friday.
Intellia Therapeutics announced a 27% workforce reduction on Friday to cut costs.
The NET Trade
Ark Invest&#8217;s Next Generation Internet ETF (ARKW) sold 7840 shares of&nbsp;Cloudflare.
The value of this trade, calculated from the closing price of $112.62, is approximately $882,608. This move was made despite NET&#8217;s stock closing at a 2.66% decrease on Friday.
The ADPT Trade
Ark Invest&#8217;s Genomic Revolution ETF sold 130,790 shares of&nbsp;Adaptive Biotechnologies.
The value of this trade, calculated from the closing price of $6.5, is approximately $850,135. This move was made despite ADPT&#8217;s stock closing at a 2.84% decrease on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 10.57% on an annualized basis producing an average annual return of 18.97%. Currently, Illumina has a market capitalization of $22.18 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $3,290.99 today based on a price of $139.84 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736268307_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Software upgrade advances complete workflow solutions
New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep
SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.
Now in the market for the first time, the single-flow-cell NovaSeq&nbsp;X Sequencing System offers the same high-quality flow cells and speed as the NovaSeq X Plus Sequencing System—Illumina's most rapidly adopted and utilized high-throughput sequencing platform to date—at a more accessible cost for labs with lower volume. The sequencers began shipping in December, and simultaneously the company introduced the software v1.3 upgrade for the NovaSeq X Series to elevate sequencing performance and advance data quality. Additionally, new NovaSeq X 25B 100- and 200-cycle kits began shipping in December, which will be key enablers of multiomic applications, including the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4335026-1&amp;h=3224067856&amp;u=https%3A%2F%2Fwww.illumina.com%2Fproducts%2Fby-type%2Fsequencing-kits%2Flibrary-prep-kits%2Fsingle-cell-rna-prep.html&amp;a=Illumina+Single-Cell+3%27+RNA+Prep">Illumina Single-Cell 3' RNA Prep</a> (Illumina Single Cell Prep), now available under Illumina's brand following the company's acquisition of Fluent.

Biotech

Illumina Announces NovaSeq X Updates With Single-Flow-Cell System, Software Upgrade, New Kits Enhancing Multiomic Capabilities

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has fallen 9.53% since its last report. The company recently reported that it has 6.51 million shares sold short, which is 4.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735138812_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 4.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Illumina?

The stock market has a well-documented tendency to deliver gains during the final trading days of December, a phenomenon known <a href="https://www.benzinga.com/24/12/42667439/us-stocks-to-open-higher-on-shortened-trading-day-as-santa-clause-rally-period-begins-says-analyst">as the &#8220;Santa Claus rally.&#8221; </a>
This period of optimism has historically brought cheer to investors, with the S&amp;P 500 gaining in 64 out of the last 96 years during the Dec. 24–Dec. 31 window, averaging a respectable 0.85% return, according to data from Seasonax.
The Santa Claus rally's most memorable performance occurred in 2018, when the S&amp;P 500 surged 6.6%, its strongest year-end rally on record. Close on its heels was 1933, which delivered a 5.5% rally.
On the flip side, 1937 and 2000 stand out as exceptions, with losses of 4.6% and 2.4%, respectively, over the same period.
The pattern holds true even during election years, offering hope to traders as 2024 wraps up. In the past 24 election years, the S&amp;P 500 has posted gains in 15 instances, averaging a modest 0.7% return. Notable rallies occurred in 2008, with a 4% rise, and in 1928, when the index climbed 3.4%.
<h3 class="wp-block-heading">10 Santa Rally Hyper Responders</h3>
For traders looking to capitalize on this seasonal tailwind, certain stocks have consistently outperformed during the Santa Claus rally window.
Here are 10 notable S&amp;P 500 stocks that have historically shone between Dec. 24 and Dec. 31 over the last 20 years:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Avg. Return</th>
<th>Median Return</th>
<th>Max Profit</th>
<th>Max Loss</th>
<th>Win Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newmont Mining Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+1.68%</td>
<td>+1.36%</td>
<td>+10.76%</td>
<td>-2.97%</td>
<td>65%</td>
</tr>
<tr>
<td>Illumina, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>+1.49%</td>
<td>+1.25%</td>
<td>+10.08%</td>
<td>-2.64%</td>
<td>60%</td>
</tr>
<tr>
<td>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+1.42%</td>
<td>+0.96%</td>
<td>+10.96%</td>
<td>-3.60%</td>
<td>60%</td>
</tr>
<tr>
<td>Assurant, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>)</td>
<td>+1.41%</td>
<td>+0.56%</td>
<td>+14.33%</td>
<td>-4.07%</td>
<td>65%</td>
</tr>
<tr>
<td>Mohawk Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</td>
<td>+1.32%</td>
<td>+1.22%</td>
<td>+8.81%</td>
<td>-3.94%</td>
<td>65%</td>
</tr>
<tr>
<td>Global Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>+1.32%</td>
<td>+0.95%</td>
<td>+8.14%</td>
<td>-1.51%</td>
<td>75%</td>
</tr>
<tr>
<td>Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</td>
<td>+1.28%</td>
<td>+0.52%</td>
<td>+9.27%</td>
<td>-2.89%</td>
<td>60%</td>
</tr>
<tr>
<td>Goldman Sachs Group, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</td>
<td>+1.27%</td>
<td>+0.39%</td>
<td>+10.40%</td>
<td>-1.41%</td>
<td>70%</td>
</tr>
<tr>
<td>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+1.25%</td>
<td>+1.13%</td>
<td>+9.63%</td>
<td>-4.70%</td>
<td>60%</td>
</tr>
<tr>
<td>Ralph Lauren Corp. (NYSE RL)</td>
<td>+1.19%</td>
<td>+0.51%</td>
<td>+8.21%</td>
<td>-2.36%</td>
<td>65%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Seasonax</figcaption></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42671903/investors-aggressively-bought-stocks-etfs-despite-fed-volatile-week-bank-of-america-reveals-largest-inflows-since-2017">Investors Aggressively Bought Stocks, ETFs In Volatile Fed Week: Bank Of America Reveals Largest Inflows Since 2017</a></li>
</ul>
Photo: Shutterstock

Santa Claus Rally: 10 S&P 500 Stocks That Consistently Outperform During Year-End Optimism

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 10.11% on an annualized basis producing an average annual return of 18.44%. Currently, Illumina has a market capitalization of $21.57 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,976.69 today based on a price of $135.99 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735056016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

It's the holiday season, but the stock market's festivities have been anything but cheerful this week.
At the week&#8217;s start traders were buoyed by a record-breaking Nasdaq 100 topping 22,000 and an optimistic outlook on interest rate cuts ahead <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">of the Federal Reserve meeting</a>.
All signs pointed to the Santa Rally – a time Wall Street traditionally celebrates with stocks climbing during the final stretch of the year – making its grand entrance yet again in 2025.
Yet, just as traders were preparing for a festive year-end bull run, the Grinch arrived midweek to throw a wrench in the celebrations.
<h3 class="wp-block-heading">The Grinch Steals The Show</h3>
Wednesday marked a dramatic turn of events as the Federal Reserve's hawkish tone sent shockwaves through the markets. 
Chair Jerome Powell delivered a lump of coal to investors by declaring a "new phase" for monetary policy. While the Fed had already cut rates by 100 basis points since September, Powell hinted at a prolonged pause, citing rates moving &#8220;meaningfully&#8221; closer to neutral territory. 
The implications were clear: the days of aggressive cuts are over. Even worse than that, the Grinch didn&#8217;t rule out the possibility of a rate hike next year. This unexpected twist sent shivers down traders&#8217; spines, leaving markets rattled.
The CBOE Volatility Index or VIX – Wall Street's so-called fear gauge – spiked over 70% on Wednesday, its sharpest single-day surge since February 2018. 
The S&amp;P 500 and Dow Jones Industrial Average recorded their worst daily performances in over two years, while tech stocks sank like a stone in deep water.
Hopes for a Santa Rally seemed to crumble as the Grinch stole the show. 
<h3 class="wp-block-heading">A Christmas Miracle?</h3>
Just when it seemed all was lost, Friday brought a glimmer of hope—the kind of plot twist only a Christmas story could deliver. 
Fresh inflation data offered an unexpected gift to traders: the Fed's personal consumption expenditure (PCE) price index rose by 2.4% in November, falling short of the anticipated 2.5%. Even more encouraging, the core PCE, which excludes volatile food and energy prices, held steady at 2.8%, undercutting predictions of 2.9%.
This softer-than-expected inflation print was the equivalent to finding a shiny new toy under the tree.
Risk appetite rebounded swiftly, with traders rushing to scoop up the stocks battered during the week's earlier sell-off. 
Sentiment brightened, and with it, the Santa Rally narrative began to regain momentum.
<h3 class="wp-block-heading">The Santa Rally And Its Legacy</h3>
The stock market has a long-standing tendency to rally during the last trading days of December. 
According to data from Seasonax, the S&amp;P 500 has posted gains during the Dec. 20–Dec. 31 period in 76 out of the past 96 years, averaging a 1.92% return. Over the last eight years, this year-end rally has been remarkably consistent, delivering positive returns each time.
In the past three decades, the S&amp;P 500 has ended the year on a high note in 24 of 30 instances. Even the losses have been relatively mild, with the most recent December downturn occurring in 2022 when the index slipped by 1.8% during the final days.
With six trading days left in 2024, traders may still have time to save the Santa Rally.
<h3 class="wp-block-heading">10 Stocks To Watch For Year-End Gains</h3>
Looking back at 20 years of data, here are 10 standout names within the S&amp;P 500 index that have consistently delivered strong year-end performances: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<th>Stock</th>
<th>Avg. Return</th>
<th>Max Gain</th>
<th>Max Loss</th>
<th>Win Ratio</th>
</tr>
<tr>
<td>Freeport-McMoRan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>)</td>
<td>+3.63%</td>
<td>+14.63%</td>
<td>-13.51%</td>
<td>90%</td>
</tr>
<tr>
<td>Illumina, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>+3.62%</td>
<td>+20.76%</td>
<td>-2.56%</td>
<td>80%</td>
</tr>
<tr>
<td>Newmont Mining Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+3.37%</td>
<td>+16.14%</td>
<td>-3.66%</td>
<td>75%</td>
</tr>
<tr>
<td>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>+3.29%</td>
<td>+13.26%</td>
<td>-5.98%</td>
<td>75%</td>
</tr>
<tr>
<td>Global Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>+3.06%</td>
<td>+9.31%</td>
<td>-2.12%</td>
<td>75%</td>
</tr>
<tr>
<td>CBRE Group, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)</td>
<td>+2.94%</td>
<td>+13.46%</td>
<td>-2.25%</td>
<td>75%</td>
</tr>
<tr>
<td>Invesco Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>)</td>
<td>+2.80%</td>
<td>+10.23%</td>
<td>-2.83%</td>
<td>70%</td>
</tr>
<tr>
<td>ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+2.73%</td>
<td>+11.45%</td>
<td>-3.78%</td>
<td>70%</td>
</tr>
<tr>
<td>Mohawk Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</td>
<td>+2.60%</td>
<td>+13.58%</td>
<td>-6.57%</td>
<td>70%</td>
</tr>
<tr>
<td>Western Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+2.59%</td>
<td>+22.24%</td>
<td>-3.78%</td>
<td>65%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42627985/which-magnificent-7-stock-will-gain-the-most-in-a-santa-claus-rally-28-select">Which Magnificent 7 Stock Will Do Best In Santa Claus Rally? Tesla Edged Out As 28% Select…</a></li>
</ul>
Photo: Courtesy of Shutterstock.

Macro Economic Events

Econ #s

Economics

Federal Reserve

CBRE

Traders Fight The Grinch To Save The Santa Rally: 10 S&P 500 Stocks Poised For A Year-End Surge

Super Micro Computer, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is trading below its 50-day moving average as it awaits removal from the Nasdaq 100 Index on <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">December 23, 2024</a>, joining the likes of Illumina, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)&nbsp;and&nbsp;Moderna, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), and Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) entered the coveted club as a replacement.
The Nasdaq-100 Index comprises 100 of the largest non-financial companies on The Nasdaq Stock Market.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a>
Established in January 1985 alongside the Nasdaq Financial-100 Index, which tracks the 100 largest financial stocks on Nasdaq, these indexes serve as benchmarks for financial instruments like options, futures, and funds.
The Nasdaq-100 undergoes an annual reconstitution each December, aligned with the quadruple witching expiration on Friday of the quarter.
Super Micro Computer stock plunged 62% in the last six months. Reportedly, the AI server company has <a target="_blank" href="https://www.benzinga.com/news/financing/24/12/42506690/super-micro-seeks-to-raise-capital-via-equity-and-debt" rel="noreferrer noopener">enlisted Evercore to</a> assist in raising capital.
The effort aims to avoid a potential delisting after the company missed its August deadline for filing its annual financial report while reviewing internal financial controls.
The company is considering private investment in public equity (PIPE) funding, which could attract interest from private equity firms. While PIPE funding provides a faster capital-raising method, it dilutes existing shareholders&#8217; equity.
Concerns still need to be made about the profitability of Super Micro&#8217;s AI-optimized servers due to reliance on high-end chips from suppliers like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Super Micro&#8217;s auditor, Ernst &amp; Young, resigned in October over governance concerns. This led to a sharp decline in stock value and prompted an independent committee to investigate. By December, the committee found no evidence of misconduct, spurring a 30% rise in Super Micro&#8217;s stock.
The company appointed BDO USA as its new auditor to address delisting risks, submitted a compliance plan to Nasdaq, and began searching for a new finance chief based on the committee&#8217;s recommendations.
Super Micro, which faced scrutiny from a Hindenburg Research report and a U.S. Department of Justice probe, has until February 25 to file its delayed financial reports.
Super Micro Computer missed the revenue estimates for the last two quarters and the adjusted EPS consensus for the last quarter.
In July 2024, Super Micro Computer <a target="_blank" href="https://www.benzinga.com/news/24/07/39847680/whats-going-on-with-super-micro-computer-shares-today" rel="noreferrer noopener">became a component</a> of the Nasdaq-100 Index and the Nasdaq-100 Equal Weighted Index, replacing Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>).
At that time, CEO Charles Liang highlighted Super Micro&#8217;s eco-friendly initiatives and AI growth opportunities during an interview with CNBC&#8217;s Jim Cramer.
Liang showcased the potential of their &#8220;liquid cooling&#8221; and &#8220;green computer&#8221; technologies to cut carbon emissions and reduce customer expenses.
He also shared his confidence in the transformative power of AI, predicting it could have a more significant impact than the industrial revolution.
The Nasdaq-100 Index underpins the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which seeks to deliver investment results mirroring the index&#8217;s performance before expenses.
Price Action: SMCI stock closed lower by 8.26% to $33.44 on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42514450/grindrs-expanding-lgbtq-market-and-20-revenue-growth-impresses-goldman-sachs" target="_blank" rel="noreferrer noopener">Grindr&#8217;s Expanding LGBTQ+ Market and 20% Revenue Growth Impresses Goldman Sachs</a></li>
</ul>
Photo via Company

AXON

MRNA

MSTR

PLTR

SMCI

Super Micro Drops Below 50-Day Average, Faces Nasdaq 100 Removal Just Months After Entry

On Friday, Nasdaq Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">opens on December 23</a>.
Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, the stock has increased around 8%, underperforming iShares Core S&amp;P Mid-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IJH#NYSE">IJH</a>).
The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png" alt="" class="wp-image-694387" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;To expand its reach in single-cell analysis and&nbsp;multiomics research, Illumina <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39714633/illumina-buys-fluent-biosciences-to-gain-stronger-foothold-in-single-cell-analysis" rel="noreferrer noopener">acquired privately-held</a> Fluent BioSciences.
Also in March, activist investor&nbsp;Carl Icahn opted against pursuing a fresh challenge to Illumina&#8217;s board, which spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.&nbsp;
Previously, Icahn had expressed intentions to remove additional directors from Illumina&#8217;s board, attributing the company&#8217;s substantial market value decline and the ill-fated $7.1 billion Grail acquisition to mismanagement by the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37671511/gene-sequencing-firm-illumina-escapes-carl-icahns-second-proxy-battle-amid-grail-divestment-effort" rel="noreferrer noopener">existing board members</a>.&nbsp;
Most recently, Illumina reported third-quarter&nbsp;adjusted EPS of $1.14, beating the consensus of $0.88, with sales&nbsp;of $1.08 billion, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41727185/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024" rel="noreferrer noopener">consensus of $1.08 billion</a>.
&#8220;During the third quarter, the Illumina team delivered strong operating results, and revenue met our expectations,&#8221; said&nbsp;Jacob Thaysen, Chief Executive Officer.
&#8220;The near-term macroeconomic environment remains constrained, and we are slightly lowering our 2024 revenue guidance,&#8221; Thaysen added.
Price Action: ILMN stock is down 0.12% at $143.70 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514376/whats-going-on-moderna-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Moderna Stock On Monday?</a></li>
</ul>
Photo via Shutterstock

GRAL

NDAQ

What's Going On With Illumina Stock On Monday?

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is trading lower on Monday. The company is expected to be removed from the Nasdaq 100 Index later this month. Here&#8217;s what you <a href="https://www.benzinga.com//node/42506977">need to know</a>.
What To Know: Super Micro is one of three companies set to be booted from the Nasdaq 100 Index on Dec. 23 as part of the index&#8217;s annual changes.
The changes will take effect before the market opens on Dec. 23. The other companies set to be removed from the index, include Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) and Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). 
The Nasdaq is set to add Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) to the index.
What Else: Super Micro has faced delays in filing its earnings for the 2024 fiscal year as well as the first quarter of the 2025 fiscal year. The company originally cited multiple reasons for the delay, including the need to find a new auditor after Ernst &amp; Young, the company&#8217;s former auditor, resigned due to governance control issues, and the need to review its internal control systems.
Super Micro has since appointed BDO USA as its independent auditor. In addition, the company&#8217;s special committee review found no evidence of misconduct.
 Lastly, the company is <a href="https://www.benzinga.com//node/42506690">working</a> with Evercore to raise its capital. The company is considering multiple options in order to achieve this, such as, a private investment in public equity.
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42510375/what-the-options-market-tells-us-about-on-holding">What the Options Market Tells Us About On Holding</a>
SMCI Price Action: At the time of writing, Super Micro stock is trading 6.75% lower at $33.98, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

What's Going On With Super Micro Computer Shares Monday?

U.S. stock futures were trading higher on Monday in premarket hours after the tech-heavy <a href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index">Nasdaq 100 index</a> extended its relentless climb last week, setting new record highs and nearing the 22,000-point milestone. The futures of all four major indices were trading higher.
The 10-year and two-year Treasury notes yielded 4.38% and 4.23%, respectively. The Federal Reserve&#8217;s upcoming meeting this week is highly anticipated by market observers.
The Federal Open Market Committee is widely expected to announce another interest rate reduction at the conclusion of their meeting on Wednesday. The probability of a further 25 basis point rate cut in December rose to 97.1% versus 61.9% a month ago, according to <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME Group&#8217;s FedWatch tool</a>.
If the Fed cuts rates, it would be the third consecutive cut, bringing the federal funds rate down from its current level of 4.50% to 4.75%. Following the meeting, Chairman Jerome Powell&#8216;s remarks will be closely scrutinized by market participants.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
Prior to that, GDP revisions on Thursday will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.31%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.20%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.10%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.27%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.20% to $605.44 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.32% to $532.25, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The Nasdaq 100 rally was driven by <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42492966/ai-driven-rally-pushes-tech-stocks-to-records-broadcom-enters-trillion-dollar-club-inflation-data-flashes-warning-signal-this-week-in-the-markets">tech giants and AI optimism</a>. It&#8217;s set to double since the start of 2023, with five of the &#8220;Magnificent Seven&#8221; stocks hitting record highs. Broadcom Inc. joined the $1 trillion market cap club after strong earnings.
The Dow Jones Industrial Average, on the other hand, fell for the seventh consecutive day on Friday and S&amp;P 500 index closed marginally lower.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dow down 7 days in a row, but only 2.6% off the all-time highs (third least ever). I see 78 7-day losing streaks since 1900 and an avg of 24.7% off ATHs.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1868406754448691224?ref_src=twsrc%5Etfw">December 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Inflation data released during the week raised some red flags. Consumer inflation rose 2.7% year-over-year in November, in line with expectations, but producer inflation jumped to 3% year-over-year, exceeding estimates of 2.6%. This marked the sharpest increase since February 2023, raising concerns about potential cost pass-throughs to consumers.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.12%</td>
<td>19,926.72</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.002%</td>
<td>6,051.09</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
<td>43,828.06</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.60%</td>
<td>2,34.90</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42492966/ai-driven-rally-pushes-tech-stocks-to-records-broadcom-enters-trillion-dollar-club-inflation-data-flashes-warning-signal-this-week-in-the-markets">AI-Driven Rally Pushes Tech Stocks To Records, Broadcom Enters Trillion-Dollar Club, Inflation Data Flashes Warning Signal: This Week In The Markets</a>
Insights From Analysts
Talking about the possibility of a &#8220;Santa Rally,&#8221; by the end of December the chief market strategist at Carson Group, Ryan Detrick shared a chart titled &#8216;Santa Comes Later In December&#8217; showing how the market has picked up after Dec. 16, on an average from 1950 to 2023.
He said, &#8220;Weak breadth, inflation heating up, bears saying they are sorry, etc, have all been listed as reasons for the recent weakness. Or maybe it is perfectly normal for stocks not to do much the first half of December, before an end-of-year rally?&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Weak breadth, inflation heating up, bears saying they are sorry, etc, have all been listed as reasons for the recent weakness. Or maybe it is perfectly normal for stocks not to do much the first half of December, before an end of year rally? Let&#39;s not give up on Santa yet. <a href="https://t.co/xo6mxsq8Yg">pic.twitter.com/xo6mxsq8Yg</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1868396543985762667?ref_src=twsrc%5Etfw">December 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He further made a case for a year-end rally in another X post. He shared a chart that compared high-yield bonds with U.S. Treasury bonds and high-beta stocks with low volatility stocks. &#8220;High yield and high beta are outperforming bonds and low volatility,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nice chart from <a href="https://twitter.com/HumbleStudent?ref_src=twsrc%5Etfw">@HumbleStudent</a> on why a year-end rally is still possible. High yield and high beta are outperforming bonds and low volatility. Risk on signals are still in play (weak breadth and all). <a href="https://t.co/VTVXgmve85">pic.twitter.com/VTVXgmve85</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1868405432550555851?ref_src=twsrc%5Etfw">December 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tom Lee, the managing partner and head of research at Fundstrat Global Advisors, hosted a webinar outlining his 2025 outlook. According to him, the S&amp;P 500 will have a better first half of the year getting up to 7,000, followed by a weaker second half of the year with us ultimately ending at 6,600
&#8220;To us, the downside risks are: DOGE too effective and GDP falls on spending cuts, (if) tariffs are actually implemented and GDP impacted,&#8221; Lee said.
Upcoming Economic Data:
Important data is slated to be released this week that will help investors determine the future course of action.
<ul>
<li>On Monday, the Empire State manufacturing survey data for December will be released at 8:30 a.m., ET.</li>
<li>The S&amp;P flash U.S. services and manufacturing PMI data for December will be released at 9:45 a.m., ET.</li>
<li>On Tuesday, U.S. retail sales data for November will be announced at 8:30 a.m., ET.</li>
<li>The industrial production and capacity utilization data for November will be announced at 9:15 a.m., ET.</li>
<li>The home builder confidence index data will be released for December at 10:00 a.m., ET.</li>
<li>And, lastly, the Federal Open Market Committee meeting will begin on Tuesday.</li>
<li>On Wednesday, housing starts, and building permit data for November will be announced at 8:30 a.m., ET.</li>
<li>The FOMC&#8217;s interest rate decision will be announced at 2:00 p.m., ET, and the Fed Chair Jerome Powell&#8217;s press conference will begin at 2:30 p.m., ET.</li>
<li>Micron Technology, Lennar, General Mills, and Toro will report earnings.</li>
<li>On Thursday, the data for initial jobless claims till Dec. 14, GDP&#8217;s second revision for the third quarter and Philadelphia Fed manufacturing survey data for December will be released at 8:30 a.m., ET.</li>
<li>Existing home sales data and U.S. leading economic indicators for November will be announced at 10:00 a.m., ET.</li>
<li>Accenture, Nike, Cintas, FedEx, and Paychex will report earnings.</li>
<li>On Friday, personal income and spending data along with core and headline PCE index data for November will be released at 8:30 a.m., ET.</li>
<li>Consumer sentiment data for December will be released at 10:00 a.m., ET.</li>
<li>Carnival Corporation and Winnebago Industries will report earnings.</li>
</ul>
Stocks In Focus:
<ul>
<li>MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) advanced 5.26%, Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) was up 0.78%, and Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) rose by 3.12% in premarket trade as Nasdaq announced on Friday that these stocks will join the Nasdaq 100 index.</li>
</ul>
<ul>
<li>Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) declined by 0.5%, Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell by 11.71% and Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) dropped by 0.99% in premarket after Nasdaq&#8217;s Friday announcement, booting these stocks off Nasdaq 100 index.</li>
</ul>
<ul>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) was up 1.57%, continuing Friday&#8217;s upmove fueled by strong quarterly earnings and upbeat AI-driven guidance for the coming year. Friday&#8217;s rally propelled the chipmaker into the exclusive $1 trillion market-cap club, making it the eighth-largest publicly traded company.</li>
</ul>
<ul>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) was 1.07% up after Wedbush&#8217;s Dan Ives hiked its price target citing AI and autonomous opportunity worth $1 trillion.</li>
</ul>
<ul>
<li>Amplitech Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) advanced 4.76% in premarket after it announced the sale of 1,352,500 shares of its common stock at $1.60 per share, totaling to price of $2.2 million.</li>
</ul>
<ul>
<li>Checkpoint Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) was up 11.44% after the U.S. Food and Drug Administration approved UnloxcyT for the treatment of adults with metastatic cutaneous squamous cell carcinoma.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were declining in the early New York session by 1.43% to hover around $70.27 per barrel.
The gold spot index rose by 0.08% to $2,677.91 per ounce. The Dollar Index was down 0.09% to 106.912 level.
Asian markets declined on Monday including Australia&#8217;s ASX 200, Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and South Korea&#8217;s Kospi Index. Most European markets also fell except Spain&#8217;s IBEX 35.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/24/12/42503379/balaji-srinivasan-contrasts-ais-reputation-as-making-it-easy-to-fake-things-with-cryptos-tamper-proof-technology">Former Coinbase Tech Chief Contrasts AI&#8217;s Reputation As Making It Easy To Fake Things With Crypto&#8217;s Tamper-Proof Technology</a></li>
</ul>
Image Via Shutterstock

Market Summary

Pre-Market Outlook

AMPG

AVGO

CKPT

TSLA

US Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December'

The much-awaited reconstitution of the Nasdaq 100 index has taken place, resulting in the addition of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) proxy MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), and Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).
This change will take effect before the market opens on Dec. 23, 2024.
What Happened:&nbsp;Nasdaq&nbsp;announced on Saturday the results of its&nbsp;annual reconstitution of the Nasdaq-100&nbsp;Index.
The Nasdaq-100 Index, a benchmark for non-financial companies on the Nasdaq, was launched in January 1985. It serves as a basis for financial products like&nbsp;options, futures, and funds.
The&nbsp;annual reconstitution aligns&nbsp;with the quadruple witch expiration&nbsp;Friday of the quarter, a strategic timing for the index.
See Also:&nbsp;<a href="https://www.benzinga.com/24/12/42477447/dogecoins-fate-tied-to-bitcoin-not-worth-overly-focusing-on-analyst-says-as-apex-memecoin-mirrors-btcs-pullback?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin&#8217;s Fate Tied To Bitcoin, Says Crypto Analyst: &#8216;Sit Back And Wait&#8217;</a>
As a result of this reconstitution,&nbsp;three companies will be removed&nbsp;from the index:&nbsp;Illumina, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>),&nbsp;Super Micro Computer, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), and&nbsp;Moderna, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
The Nasdaq-100 Index is integral to the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which seeks to mirror the index&#8217;s performance. Options, futures, and structured products based on the Nasdaq-100 Index and the Invesco QQQ Trust are traded on various exchanges.
Why It Matters: The inclusion of&nbsp;MicroStrategy&nbsp;in the Nasdaq-100 could significantly boost its visibility and attract fresh inflows from major ETFs like QQQ.
Analysts at Bernstein have suggested that this move, combined with MicroStrategy&#8217;s aggressive&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42433049/microstrategy-nasdaq-100-inclusion-on-the-horizon-could-spell-59-upside-says-bernstein">Bitcoin acquisition strategy</a>, could lead to a 59% upside for the company, with a target price of $600.
Meanwhile,&nbsp;Palantir&nbsp;is positioned to become &#8220;the next Oracle&#8221; in 2025, according to Wedbush Securities' Dan Ives. The company&#8217;s AI platform is seen as a transformative force in enterprise operations, with significant results already demonstrated through its Warp Speed manufacturing operating system.
This development could further enhance Palantir&#8217;s standing in both government and commercial sectors, as highlighted in Ives&#8217;&nbsp;<a href="https://www.benzinga.com/24/12/42453057/palantir-positioned-to-become-the-next-oracle-in-2025-says-dan-ives-messi-of-ai-set-for-breakout-year">annual sector outlook</a>.
On the other hand,&nbsp;Super Micro Computer&nbsp;finds itself removed from the index, despite benefiting from the surging demand for AI infrastructure. The company faced challenges due to a <a href="https://www.benzinga.com/24/12/42445956/smci-teeters-on-edge-of-nasdaq-100-is-friday-d-day-for-super-micro">recent auditing scandal</a>, which significantly impacted its market capitalization.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42452955/shiba-inu-poised-for-180-upside-says-analyst-hodlers-keep-selling?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shiba Inu Poised For 180% Upside, Says Analyst — HODLers Keep Selling</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

$BTC

MicroStrategy, Palantir, Axon Added To Nasdaq 100: Super Micro Computer, Moderna, Illumina Exit The Index

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Truist Securities analyst Jake Bartlett downgraded Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) from Buy to Hold and lowered the price target from $56 to $36. Dave &amp; Buster&#8217;s shares closed at $36.80 on Tuesday. <a href="https://www.benzinga.com/quote/PLAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan analyst Pinjalim Bora downgraded the rating for C3.ai, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Neutral to Underweight and announced a $28 price target. C3.ai shares closed at $41.73 on Tuesday. <a href="https://www.benzinga.com/quote/AI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Matthew Bouley downgraded D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) from Overweight to Equal-Weight and lowered the price target from $192 to $170. D.R. Horton shares closed at $157.00 on Tuesday. See how other analysts view this stock.</li>
<li>Citigroup analyst Patrick Donnelly downgraded the rating for Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Buy to Neutral and lowered the price target from $190 to $165. Illumina shares closed at $148.53 on Tuesday. <a href="https://www.benzinga.com/quote/ILMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Elyse Greenspan downgraded the rating for The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Equal-Weight to Underweight and lowered the price target from $256 to $217. Travelers shares closed at $247.65 on Tuesday. <a href="https://www.benzinga.com/quote/TRV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DHI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="615" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11082723/image-91-1024x615.png" alt="" class="wp-image-687385" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11082723/image-91-1024x615.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11082723/image-91-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11082723/image-91-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11082723/image-91.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<a href="https://www.benzinga.com/news/earnings/24/12/42429181/macys-adobe-and-3-stocks-to-watch-heading-into-wednesday">Macy&#8217;s, Adobe And 3 Stocks To Watch Heading Into Wednesday</a>

Downgrades

PLAY

This D.R. Horton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Sees Q4 revenue $1.1B, consensus $1.07B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

Illumina sees Q4 EPS 91c-93c, consensus 92c

Illumina reports preliminary Q4 results, provides 2025 expectations

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Eli Lilly (LLY) cut its FY24 rev...

Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz

Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Bernstein analyst Eve Burstein maintained a Hold rating on Illumina (ILMN – Research Report) today. The company's shares opened today at $145.25. A...

Bernstein Sticks to Their Hold Rating for Illumina (ILMN)

Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Illumina (ILMN – Research Report) today and set a price target of $12...

Illumina's Stagnant Revenue Projections and Market Headwinds Justify Sell Rating

Patrick B Donnelly, an analyst from Citi, maintained the Hold rating on Illumina (ILMN – Research Report). The associated price target remains the ...

Illumina's Hold Rating: Balancing Revenue Growth with Market Uncertainties

20:06 EST Cathie Wood's ARK Investment buys 11.5K shares of Illumina (ILMN) today Published first on TheFly – the ultimate source for real-time, ma...

Cathie Wood's ARK Investment buys 11.5K shares of Illumina today

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research Report)...

Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Illumina (ILMN) and RegenXBio (RGNX)

Grail 2024 revenue guidance range above consensus

ACMR

AEHR

ALUR

AMZN

ANGI

APLD

CART

CHGG

GOOG

GOOGL

HEES

KULR

NAMS

QTRX

RGNX

TDOC

Press Releases

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

Illumina To Webcast Upcoming Investor Conference

Annual Changes to the Nasdaq-100 Index®

Ovation.io and Illumina Collaborate to Advance Genomic Data Research

Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications

Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025

Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Illumina and NVIDIA collaborate to decode biology and propel precision health

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025

MYGN

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Morgan Stanley

Citigroup

Stephens & Co.

Piper Sandler

Baird

엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 제품은 GPU와 게임에 국한되지 않는다. 이 기술 회사는 현재 <a href="https://www.benzinga.com/topic/artificial-intelligence">헬스케어 인공지능</a> 분야에서도 주목받고 있다.
월요일에 열린 J.P. 모건의 헬스케어 컨퍼런스에서 애널리스트 할란 서(Harlan Sur)는 엔비디아의 전략적 위치와 향후 성장의 주요 동력을 강조했다. 이것이 월스트리트와 병원들이 주목하고 있는 이유이다.
<h2 class="wp-block-heading">AI 에이전트가 구원투수로 나선다</h2>
최대 2,000만 명의 의료 인력 부족이 우려되는 상황에서, 엔비디아는 배달 로봇과 임상 대화를 위한 생성적 인공지능(AI)과 같은 AI 기반 솔루션으로 나섰다. 서는 노동력 부족으로 인한 이러한 에이전트 AI 솔루션에 대한 수요가 증가하고 있으며, 엔비디아가 이미 인트리보(Intrivo)와 어브릿지(Abridge)와 같은 회사와 협력하여 이러한 기술을 배포하고 있다고 언급했다.
이러한 &#8220;디지털 헬스 에이전트&#8221;는 단순한 미래형 장난감이 아니라, 중요한 인력 격차를 채우는 데 필수적인 역할을 하고 있다. 인트리보와 어브릿지와 같은 파트너십은 엔비디아가 얻고 있는 실제적인 추진력을 강조한다.
또한 읽어보기: <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">젠슨 황, 양자 컴퓨팅은 20년 후라고 했지만, 엔비디아는 전략적 채용에 대규모 투자</a>
<h2 class="wp-block-heading">엔비디아: 대형 플랫폼, 더 큰 야망</h2>
엔비디아의 강력한 데이터 센터 플랫폼인 옴니버스(Omniverse), 코스모스(Cosmos) 및 DGX 클라우드는 헬스케어 AI 채택을 새로운 차원으로 끌어올리고 있다. 서에 따르면, 온프레미스, 클라우드 기반 또는 하이브리드 모델 전반에 걸친 유연성은 기업 채택을 촉진하는 데 도움이 된다.
2026 회계연도까지 연간 10억 달러의 반복적인 헬스케어 매출이 예상되는 가운데, 이 회사는 수천억 달러 규모의 시장을 겨냥하고 있다.
<h2 class="wp-block-heading">엔비디아의 기술이 의학과 만나다</h2>
약물 발견에서 로봇 보조 수술에 이르기까지, 엔비디아는 AI를 의료 기기와 병원 운영 전반에 통합한다. 서는 엔비디아가 로봇 훈련과 의료 기술 개발을 위한 물리적 환경을 만들기 위해 옴니버스와 코스모스 플랫폼을 사용하고 있다고 강조했다.
<h2 class="wp-block-heading">유전체학, 파트너십, 경쟁력</h2>
아이큐비아 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) 및 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)와의 새로운 협력은 엔비디아의 헬스케어 AI 지배를 향한 공격적인 추진을 나타낸다. 서는 이러한 전략적 파트너십이 엔비디아의 헬스케어 AI 로드맵에서 중요한 단계라고 언급했다.
약물 발견에서 유전체 연구에 이르기까지, 엔비디아는 인류 건강을 재편할 수 있는 혁신을 열어주기 위해 노력하고 있다.
서의 전망이 맞다면, 헬스케어 AI는 엔비디아의 다음 10억 달러 규모의 기회가 될 수 있다.
다음으로 읽어보세요: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A1%B0-%EB%B0%94%EC%9D%B4%EB%93%A0-vs-%EC%A0%A0%EC%8A%A8-%ED%99%A9-%EC%83%88%EB%A1%9C%EC%9A%B4-%EC%B9%A9-%EC%88%98%EC%B6%9C-%EA%B7%9C%EC%A0%9C%EA%B0%80-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84/" target="_blank" rel="noopener">조 바이든 vs 젠슨 황: 백악관의 새로운 칩 수출 규제가 엔비디아에 미치는 의미</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 클라우드플레어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)의 주요 회사들에서 상당한 거래를 진행했다.
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div></div>
</div>
</div>
</div>
RXRX 거래
아크 인베스트(Ark Invest)의 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)가 리커젼 파마슈티컬스의 주식 264,596주를 대량으로 매수했다.
이 거래의 가치는 종가인 6.88달러를 기준으로 약 1.82 백만 달러이다. 이 결정은 금요일에 RXRX의 주가가 5.23% 하락한 것에도 불구하고 이루어졌다.
ILMN 거래
아크 인베스트의 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARK Innovation ETF가 일루미나의 주식을 매수했다.
ARKG는 4,038주를 매수했고, ARKK는 11,425주를 매수했다. 이 거래들의 총 가치는 종가인 136.69달러를 기준으로 약 1.97 백만 달러이다.
이 결정은 일루미나의 주가가 금요일에 2.14% 하락한 것에도 불구하고 이루어졌다.
참고: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">비트코인 슈퍼사이클이 온다, 경제학자가 말하지만, 함정이 있다</a>
NTLA 거래
아크 인베스트의 Genomic Revolution ETF와 ARK Innovation ETF가 인텔리아 테라퓨틱스의 주식을 매수했다.
ARKG는 41,503주를 매수했고, ARKK는 124,799주를 매수했다.
이 거래들의 총 가치는 종가인 10.2달러를 기준으로 약 1.46 백만 달러이다. 이 결정은 NTLA의 주가가 금요일에 15.14% 하락한 것에도 불구하고 이루어졌다.
인텔리아 테라퓨틱스는 금요일에 비용 절감을 위해 27%의 인력 감축을 발표했다.
NET 거래
아크 인베스트의 Next Generation Internet ETF(ARKW)가 클라우드플레어의 주식 7,840주를 매도했다.
이 거래의 가치는 종가인 112.62달러를 기준으로 약 882,608달러이다. 이 결정은 NET의 주가가 금요일에 2.66% 하락한 것에도 불구하고 이루어졌다.
ADPT 거래
아크 인베스트의 Genomic Revolution ETF가 어댑티브 바이오테크놀로지스의 주식 130,790주를 매도했다.
이 거래의 가치는 종가인 6.5달러를 기준으로 약 850,135달러이다. 이 결정은 ADPT의 주가가 금요일에 2.84% 하락한 것에도 불구하고 이루어졌다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">마크 저커버그가 &#8216;문화적으로 무력화된&#8217; 기업들을 비판하고, 메타가 DEI 프로그램을 중단하자 &#8216;남성 에너지&#8217;를 옹호하다</a></li>
</ul>
면책조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 생성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
사진 제공: Ark Invest


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

주식 시장은 12월 마지막 거래일에 이익을 얻는 경향이 있다는 사실이 잘 입증되어 있습니다. 이는 <a href="https://www.benzinga.com/24/12/42667439/us-stocks-to-open-higher-on-shortened-trading-day-as-santa-clause-rally-period-begins-says-analyst">&#8220;산타 클로스 랠리&#8221;</a>로 알려진 현상이다.
이 낙관적인 시기는 역사적으로 투자자들에게 기쁨을 안겨주었으며, S&amp;P 500 지수가 지난 96년 중 64년에서 12월 24일부터 12월 31일 사이에 상승하여 평균 0.85%의 괜찮은 수익률을 기록했다. 이는 시즌액스(Seasonax)의 데이터에 따른 것이다.
산타 랠리의 가장 기억에 남는 성과는 2018년에 발생했으며, 이때 S&amp;P 500이 6.6% 급등하여 기록상 가장 강력한 연말 랠리를 기록했다. 1933년에도 5.5%의 상승률을 기록하며 뒤를 이었다.
반면, 1937년과 2000년은 예외적으로 같은 기간 동안 각각 4.6%와 2.4%의 손실을 기록했다.
선거 연도에도 이 패턴은 유지되어, 2024년이 마무리될 때 트레이더들에게 희망을 제공한다. 지난 24년의 선거 연도 중 S&amp;P 500은 15번 상승하여 평균 0.7%의 소폭 상승률을 기록했다. 2008년에는 4% 상승, 1928년에는 3.4% 상승하는 주목할만한 랠리가 발생했다.
<h3 class="wp-block-heading">산타 랠리의 10대 하이퍼 반응 주식</h3>
이 계절적 호재를 활용하고자 하는 트레이더들을 위해, 특정 주식들이 산타 랠리 기간 동안 지속적으로 우수한 성과를 보였다.
다음은 지난 20년 동안 12월 24일부터 12월 31일 사이에 역사적으로 두각을 나타낸 10개의 주목할 만한 S&amp;P 500 주식이다:
<figure class="wp-block-table is-style-stripes">
<table>
<thead>
<tr>
<th>회사</th>
<th>평균 수익률</th>
<th>중간 수익률</th>
<th>최대 수익</th>
<th>최대 손실</th>
<th>승률</th>
</tr>
</thead>
<tbody>
<tr>
<td>뉴몬트 마이닝 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+1.68%</td>
<td>+1.36%</td>
<td>+10.76%</td>
<td>-2.97%</td>
<td>65%</td>
</tr>
<tr>
<td>일루미나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>+1.49%</td>
<td>+1.25%</td>
<td>+10.08%</td>
<td>-2.64%</td>
<td>60%</td>
</tr>
<tr>
<td>웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+1.42%</td>
<td>+0.96%</td>
<td>+10.96%</td>
<td>-3.60%</td>
<td>60%</td>
</tr>
<tr>
<td>어슈어런트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>)</td>
<td>+1.41%</td>
<td>+0.56%</td>
<td>+14.33%</td>
<td>-4.07%</td>
<td>65%</td>
</tr>
<tr>
<td>모호크 인더스트리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</td>
<td>+1.32%</td>
<td>+1.22%</td>
<td>+8.81%</td>
<td>-3.94%</td>
<td>65%</td>
</tr>
<tr>
<td>글로벌 페이먼츠 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>+1.32%</td>
<td>+0.95%</td>
<td>+8.14%</td>
<td>-1.51%</td>
<td>75%</td>
</tr>
<tr>
<td>월트 디즈니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</td>
<td>+1.28%</td>
<td>+0.52%</td>
<td>+9.27%</td>
<td>-2.89%</td>
<td>60%</td>
</tr>
<tr>
<td>골드만삭스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</td>
<td>+1.27%</td>
<td>+0.39%</td>
<td>+10.40%</td>
<td>-1.41%</td>
<td>70%</td>
</tr>
<tr>
<td>온 세미컨덕터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+1.25%</td>
<td>+1.13%</td>
<td>+9.63%</td>
<td>-4.70%</td>
<td>60%</td>
</tr>
<tr>
<td>랄프 로렌 (NYSE RL)</td>
<td>+1.19%</td>
<td>+0.51%</td>
<td>+8.21%</td>
<td>-2.36%</td>
<td>65%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">데이터 출처: Seasonax</figcaption></figure>
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42671903/investors-aggressively-bought-stocks-etfs-despite-fed-volatile-week-bank-of-america-reveals-largest-inflows-since-2017">투자자들이 연준의 변동성 있는 주간에도 주식과 ETF를 공격적으로 매수: 뱅크 오브 아메리카가 2017년 이후 최대 유입을 발표</a></li>
</ul>
사진: Shutterstock

산타 랠리: 연말 기간 동안 일관되게 우수한 성과를 보여주는 S&P 500 주식 10종

연말 연휴 시즌이지만, 이번 주 주식 시장의 축제 분위기는 그리 유쾌하지 않았다.
주 초에는 나스닥 100이 22,000을 돌파하며 사상 최고치를 기록하고, <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025" target="_blank" rel="noopener" data-google-interstitial="false">연방준비제도(연준) 회의</a>를 앞두고 금리 인하에 대한 낙관적인 전망으로 트레이더들이 고무된 상황이었다.
모든 징후는 월스트리트가 전통적으로 연말 마지막에 주가가 상승하는 &#8216;산타 랠리&#8217;를 다시 한번 맞이할 것으로 보였다.
그러나 트레이더들이 축제 분위기의 연말 강세장을 준비하던 중, 주 중반에 &#8216;그린치(Grinch)&#8217;가 등장하여 축제에 찬물을 끼얹었다.
<h3 class="wp-block-heading">그린치가 쇼를 훔쳐갔다</h3>
수요일은 연준의 매파적인 발언이 시장에 충격파를 가하면서 극적인 전환을 맞이했다.
연준 의장 제롬 파월은 투자자들에게 &#8220;새로운 단계&#8221;의 통화 정책을 선언하며 원치 않는 선물(a lump of coal)을 안겨주었다. 연준이 이미 9월 이후 100bp(베이시스포인트) 금리를 인하했음에도 불구하고, 파월은 중립 지대로 &#8220;상당히&#8221; 가까워졌다고 언급하며 장기적인 일시 정지를 시사했다.
명확한 의미는 공격적인 금리 인하 시대가 끝났다는 것이었다. 더 나쁘게도, 그린치는 내년에 금리 인상 가능성을 배제하지 않았다. 이 예상치 못한 전개는 트레이더들에게 전율을 일으키고 시장을 흔들리게 했다.
시카고 옵션 거래소 변동성 지수(VIX), 소위 월스트리트의 공포 지표가 수요일에 70% 이상 급등하며 2018년 2월 이후 가장 큰 단일일 상승폭을 기록했다.
S&amp;P 500과 다우존스 산업평균지수는 2년 이상 만에 가장 나쁜 하루 성과를 기록했으며, 기술주들은 깊은 물속으로 가라앉았다.
산타 랠리에 대한 희망은 그린치가 쇼를 훔쳐가면서 무너지는 듯 보였다.
<h3 class="wp-block-heading">크리스마스 기적?</h3>
모든 것이 잃어버린 것처럼 보일 때, 금요일에는 크리스마스 이야기에서나 나올 법한 반전의 희망이 찾아왔다.
최신 인플레이션 데이터는 트레이더들에게 예상치 못한 선물을 안겨주었다. 연준의 개인소비지출(PCE) 물가 지수가 11월에 2.4% 상승하여 예상된 2.5%를 밑돌았다. 더욱 고무적인 것은, 변동성이 큰 음식과 에너지 가격을 제외한 핵심 PCE가 2.8%로 안정세를 유지하며 2.9% 예상을 하회한 것이다.
예상보다 낮은 인플레이션 수치는 마치 크리스마스 트리 아래에서 반짝이는 새 장난감을 발견한 것과 같았다.
위험 선호도가 빠르게 반등하며, 트레이더들은 주 초에 매도세로 타격을 입었던 주식들을 사기 위해 몰려들었다.
시장 분위기는 밝아졌고, 이에 따라 산타 랠리의 내러티브도 다시 모멘텀을 되찾기 시작했다.
<h3 class="wp-block-heading">산타 랠리와 그 유산</h3>
주식 시장은 12월 마지막 거래일에 상승하는 경향이 오랜 역사를 가지고 있다.
시즌액스(Seasonax)의 데이터에 따르면, S&amp;P 500은 12월 20일부터 31일 사이에 76년 중 96년에서 상승세를 보였으며, 평균적으로 1.92%의 수익률을 기록했다. 지난 8년간은 이 연말 랠리가 매우 일관되게 긍정적인 수익을 제공하였다.
지난 30년 동안 S&amp;P 500은 30회 중 24회에서 연말을 높은 가격으로 마감했다. 심지어 손실도 상대적으로 경미했으며, 가장 최근의 12월 하락은 2022년에 발생하여 지수가 마지막 며칠 동안 1.8% 하락했다.
2024년 마지막 거래일이 6일 남은 지금, 트레이더들은 여전히 산타 랠리를 구할 시간이 있을지도 모른다.
<h3 class="wp-block-heading">연말 상승을 위한 주목할 10개 주식</h3>
지난 20년의 데이터를 바탕으로, S&amp;P 500 지수에서 강력한 연말 성과를 지속적으로 기록한 10개의 주식들을 소개한다:
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<th>주식</th>
<th>평균 수익률</th>
<th>최대 상승</th>
<th>최대 하락</th>
<th>승률</th>
</tr>
<tr>
<td>프리포트 맥모란 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>)</td>
<td>+3.63%</td>
<td>+14.63%</td>
<td>-13.51%</td>
<td>90%</td>
</tr>
<tr>
<td>일루미나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>+3.62%</td>
<td>+20.76%</td>
<td>-2.56%</td>
<td>80%</td>
</tr>
<tr>
<td>뉴몬트 마이닝 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+3.37%</td>
<td>+16.14%</td>
<td>-3.66%</td>
<td>75%</td>
</tr>
<tr>
<td>모자이크 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>+3.29%</td>
<td>+13.26%</td>
<td>-5.98%</td>
<td>75%</td>
</tr>
<tr>
<td>글로벌 페이먼츠 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>+3.06%</td>
<td>+9.31%</td>
<td>-2.12%</td>
<td>75%</td>
</tr>
<tr>
<td>CBRE 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)</td>
<td>+2.94%</td>
<td>+13.46%</td>
<td>-2.25%</td>
<td>75%</td>
</tr>
<tr>
<td>인베스코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>)</td>
<td>+2.80%</td>
<td>+10.23%</td>
<td>-2.83%</td>
<td>70%</td>
</tr>
<tr>
<td>온 세미컨덕터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+2.73%</td>
<td>+11.45%</td>
<td>-3.78%</td>
<td>70%</td>
</tr>
<tr>
<td>모호크 인더스트리스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</td>
<td>+2.60%</td>
<td>+13.58%</td>
<td>-6.57%</td>
<td>70%</td>
</tr>
<tr>
<td>웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+2.59%</td>
<td>+22.24%</td>
<td>-3.78%</td>
<td>65%</td>
</tr>
</tbody>
</table>
</figure>
지금 읽어보세요: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42627985/which-magnificent-7-stock-will-gain-the-most-in-a-santa-claus-rally-28-select">산타 클로스 랠리에서 가장 많이 상승할 매그니피센트 7 주식은? 테슬라가 28%로 1위!</a></li>
</ul>
사진: Shutterstock 제공.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

산타 랠리를 위해 그린치와 싸우는 트레이더들: 연말 급등을 예상하는 S&P 500 주식 10개

나스닥 100 지수에서 <a href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" target="_blank" rel="noreferrer noopener">2024년 12월 23일</a>에 제거될 예정인 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 월요일 8% 이상 급락하며 50일 이동 평균선 아래로 마감되었다.
이는 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)와 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)와 같은 기업들과 같은 처지다.
팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) 그리고 엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>)는 대체 기업으로서 이 유명한 클럽에 들어갔다.
나스닥-100 지수는 나스닥 주식 시장에서 가장 큰 100개 비금융 회사들을 포함한다.
추가 읽기: <a href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" target="_blank" rel="noreferrer noopener">허브스팟은 AI 기반 플랫폼으로 SMB CRM 시장을 지배할 것이라고 BofA 애널리스트가 말했다.</a>
이 지수는 1985년 1월 나스닥에서 가장 큰 100개 금융 주식을 추적하는 나스닥 금융-100 지수와 함께 설립되었으며, 이 지수들은 옵션, 선물 및 펀드와 같은 금융 상품의 벤치마크 역할을 한다.
나스닥-100은 매년 12월 분기 금요일의 네 마녀의 날 만기일에 맞춰 매년 재구성을 거친다.
&#x2A;&#x2A;참고: 네 마녀의 날은 주가지수 선물과 옵션, 개별 주식 선물과 옵션 등 네 가지 파생상품의 만기일이 겹치는 날을 말한다. 쿼드러플 위칭데이(Quadruple Witching Day)라고도 불리며, 매년 3월, 6월, 9월, 12월의 둘째 목요일에 발생한다.
슈퍼 마이크로 컴퓨터 주식은 지난 6개월 동안 62% 하락했다. 이 인공지능(AI) 서버 회사는 <a href="https://www.benzinga.com/news/financing/24/12/42506690/super-micro-seeks-to-raise-capital-via-equity-and-debt" target="_blank" rel="noreferrer noopener">에버코어를 통해</a> 자본을 조달하려 하고 있다.
이 노력은 회사가 내부 재무 통제를 검토하는 동안 8월 재무 연례 보고서 제출 기한을 놓친 후 발생할 수 있는 상장 폐지 위험을 피하기 위한 것이다.
이 회사는 사모 투자 지분(PIPE) 자금 조달을 고려하고 있으며, 이는 사모 펀드 회사들의 관심을 끌 수 있다. PIPE 자금 조달은 더 빠른 자본 조달 방법을 제공하지만 기존 주주의 지분을 희석시킨다.
슈퍼 마이크로의 AI 최적화 서버의 수익성에 대한 우려는 여전히 존재한다. 이는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 같은 공급업체들의 고급 칩에 대한 의존성 때문이다.
슈퍼 마이크로의 감사인인 언스트 &amp; 영(Ernst &amp; Young)은 10월에 거버넌스 문제로 사임했다. 이는 주가의 급락을 초래하고 독립 위원회에 조사를 촉발했다. 12월에는 이 위원회가 위반 증거를 찾지 못했다고 밝혀 슈퍼 마이크로 주식이 30% 상승했다.
이 회사는 BDO USA를 새로운 감사인으로 임명하여 상장 폐지 위험을 해결하고, 나스닥에 준수 계획을 제출했으며, 위원회의 권고에 따라 새로운 재무 책임자를 찾기 시작했다.
슈퍼 마이크로는 힌덴버그 리서치(Hindenburg Research) 보고서와 미국 법무부 조사에서 조사를 받았으며, 2월 25일까지 연기된 재무 보고서를 제출해야 한다.
슈퍼 마이크로 컴퓨터는 지난 두 분기 동안 매출 추정치를 미달했으며, 마지막 분기의 조정 EPS 컨센서스를 미달했다.
2024년 7월, 슈퍼 마이크로 컴퓨터는 <a href="https://www.benzinga.com/news/24/07/39847680/whats-going-on-with-super-micro-computer-shares-today" target="_blank" rel="noreferrer noopener">나스닥-100 지수</a>와 나스닥-100 동등 가중 지수의 구성 요소가 되었으며, 월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)를 대체했다.
그 당시 CEO 찰스 리앙(Charles Liang)은 CNBC의 짐 크레이머와의 인터뷰에서 슈퍼 마이크로의 친환경 이니셔티브와 AI 성장 기회를 강조했다.
리앙은 &#8220;액체 냉각&#8221; 및 &#8220;친환경 컴퓨터&#8221; 기술의 잠재력을 보여주어 탄소 배출량을 줄이고 고객 비용을 절감할 수 있다고 언급했다.
그는 또한 AI의 변혁적 힘에 대한 확신을 공유하며, AI가 산업 혁명보다 더 큰 영향을 미칠 것이라고 예측했다.
나스닥-100 지수는 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)의 기초가 된다. QQQ는 지수의 성과를 비용 전 투자 결과와 일치시키기 위해 노력한다.
가격 동향: SMCI 주식은 월요일에 8.26% 하락한 33.44달러로 마감했다. 이후 시간외 거래에서 1.17% 추가 하락했다.
추가 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42514450/grindrs-expanding-lgbtq-market-and-20-revenue-growth-impresses-goldman-sachs" target="_blank" rel="noreferrer noopener">그라인더의 LGBTQ+ 시장 확대와 20% 매출 성장률이 골드만삭스에 인상적이다.</a></li>
</ul>
회사 제공 사진
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

진입 몇 달 만에 나스닥 100에서 제외 위기에 처한 슈퍼 마이크로 8% 이상 급락

많이 기다려온 나스닥 100 지수의 재편성이 이루어졌다. 이로 인해 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)의 대체 자산으로 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 및 엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>)가 추가되었다.
이 변화는 2024년 12월 23일 시장 개장 전에 발효된다.
무슨 일이 있었나: 나스닥은 토요일에 나스닥-100 지수의 연례 재편성 결과를 발표했다.
나스닥-100 지수는 나스닥에 상장된 비금융 회사들의 기준 지수로서 1985년 1월에 출시되었다. 이 지수는 옵션, 선물 및 펀드와 같은 금융 상품의 기초가 된다.
나스닥-100은 매년 12월 분기 금요일의 4중 마녀 만기일에 맞춰 매년 재구성을 거친다.
참고: <a href="https://www.benzinga.com/24/12/42477447/dogecoins-fate-tied-to-bitcoin-not-worth-overly-focusing-on-analyst-says-as-apex-memecoin-mirrors-btcs-pullback?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">도지코인의 운명은 비트코인에 달려 있다, 암호화폐 분석가가 말함: &#8216;앉아서 기다리세요&#8217;</a>
이 재편성의 결과로 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) 및 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)가 이 지수에서 제외될 것이다.
나스닥-100 지수는 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)의 중요한 구성 요소로, QQQ는 지수의 성과를 추적하려고 한다. 나스닥-100 지수와 Invesco QQQ Trust를 기반으로 한 옵션, 선물 및 구조화 상품은 다양한 거래소에서 거래된다.
왜 중요한가: 마이크로스트레티지가 나스닥-100에 포함됨으로써 그 회사의 가시성이 크게 높아지고 QQQ와 같은 주요 ETF로부터 새로운 자금 유입을 유치할 수 있다.
번스타인의 애널리스트들은 이 움직임과 마이크로스트레티지의 공격적인 <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42433049/microstrategy-nasdaq-100-inclusion-on-the-horizon-could-spell-59-upside-says-bernstein">비트코인 인수 전략</a>이 결합되어 회사에 59%의 상승 여력을 가져다줄 수 있으며, 목표 주가가 600달러에 이를 것이라고 제안했다.
한편, 팔란티어는 2025년까지 &#8220;다음 오라클&#8221;이 될 가능성이 있다고 웨드부시 증권의 댄 아이브스가 말했다. 이 회사의 인공지능(AI) 플랫폼은 기업 운영에서 혁신적인 힘으로 간주되며, 워프 스피드(Warp Speed) 제조 운영 시스템을 통해 이미 상당한 결과를 보여주었다.
이 발전은 팔란티어의 정부 및 상업 부문에서의 입지를 더욱 강화할 수 있으며, 이는 아이브스의 <a href="https://www.benzinga.com/24/12/42453057/palantir-positioned-to-become-the-next-oracle-in-2025-says-dan-ives-messi-of-ai-set-for-breakout-year">연례 부문 전망</a>에 강조된 바 있다.
반면, 슈퍼 마이크로 컴퓨터는 AI 인프라 수요 급증의 혜택을 받았음에도 불구하고 지수에서 제외되었다. 이 회사는 <a href="https://www.benzinga.com/24/12/42445956/smci-teeters-on-edge-of-nasdaq-100-is-friday-d-day-for-super-micro">최근 회계 스캔들</a>로 인해 시장 가치에 큰 영향을 받아 어려움을 겪었다.
다음 읽을 거리:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42452955/shiba-inu-poised-for-180-upside-says-analyst-hodlers-keep-selling?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">시바 이누, 180% 상승 가능성 있다고 분석가가 말함 — 보유자들은 계속해서 매도 중</a></li>
</ul>
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 제작되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

마이크로스트레티지, 팔란티어 및 엑슨이 나스닥 100에 추가: SMCI 및 MRNA 등은 제외

S&amp;P 500과 나스닥 100이 월요일 상승세를 이어갔다. 이로써 두 지수는 모두 8일 연속으로 상승을 기록하며 연방준비제도(연준)의 <a href="https://www.benzinga.com/topic/interest-rates">금리 인하</a>를 앞두고 미국 경제 전망과 금융 상황이 개선됨에 따라 트레이더들이 낙관론을 유지하고 있는 것을 보여준다.
S&amp;P 500의 경우 이는 2024년 5월 이후 가장 긴 연승을 기록하는 반면, 기술주 중심의 나스닥 100은 2023년 10월 이후 이러한 연속 상승을 본 적이 없다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500은 월요일 0.95% 상승하여 7월 중순에 도달한 사상 최고치의 1% 이내로 마감했다. S&amp;P 500 기업 중 거의 95%가 2분기 실적을 보고했다. 팩트셋(FactSet)의 데이터에 따르면 이들 기업 중 79%가 주당순이익(EPS) 기대치를 초과했으며, 60%는 예상보다 높은 매출을 기록했다. S&amp;P 500의 전년 대비 혼합 실적 성장률은 10.9%로 2021년 4분기 이후 가장 높았다.
Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)를 통해 모니터링되는 나스닥 100은 1.3% 높게 마감했지만 사상 최고치보다 4.6% 낮은 수준을 유지하고 있다.
베테랑 월스트리트 투자자 에드 야데니(Ed Yardeni)는 월요일 메모에서 &#8220;지난주에는 근거 없는 미국 경기 침체에 대한 우려와 글로벌 금융 시장 불안이 도래하자마자 빠르게 사라졌다&#8221;고 썼다.
월요일 세션에서는 경제 데이터가 발표되지 않았지만 투자자들은 유명한 매파인 미니애폴리스 연은 총재인 닐 카시카리의 논평에 긍정적인 반응을 보였다. 그는 월스트리트 저널과의 독점 인터뷰에서 9월 금리 인하 가능성을 암시했다.
CME 그룹의 페드워치(FedWatch) 도구에 따르면 현재 시장 내재 확률은 9월에 25bp(베이시스 포인트) 인하할 확률이 77.5%이며, 50bp 인하할 가능성은 22.5%이다.
이번 주 트레이더들은 8월 22일부터 24일까지 예정된 <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40446287/investors-look-for-clues-on-september-rate-cut-at-jackson-hole-how-does-stock-mar" target="_blank" rel="noopener" data-google-interstitial="false">잭슨 홀 심포지엄</a>에서 주요 통화 정책 논의를 면밀히 지켜볼 예정이며, 제롬 파월 연준 의장이 금요일 오전 10시에 연설할 예정이다.
야데니는 &#8220;연준이 너무 많은 완화 조치를 취하고 추가 금리 인하에 대한 기대를 억제하지 않는다면 엔화는 다시 강세를 보여 캐리 트레이드 청산의 두 번째 물결을 촉발할 수 있다&#8221;고 경고했다.
<h3 class="wp-block-heading">월요일 S&amp;P 500의 주요 상승 기업</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>기업</td>
<td>1일 수익률 (%)</td>
</tr>
<tr>
<td>EQT 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</td>
<td>4.93</td>
</tr>
<tr>
<td>어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>4.52</td>
</tr>
<tr>
<td>다덴 레스토랑 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)</td>
<td>4.41</td>
</tr>
<tr>
<td>앨버말 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>4.31</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>4.31</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">월요일 나스닥 100의 주요 상승 기업</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>기업</td>
<td>1일 수익률 (%)</td>
</tr>
<tr>
<td>어드밴스드 마이크로 디바이시스.</td>
<td>4.52</td>
</tr>
<tr>
<td>엔비디아</td>
<td>4.31</td>
</tr>
<tr>
<td>일루미나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>4.25</td>
</tr>
<tr>
<td>덱스콤 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</td>
<td>4.10</td>
</tr>
<tr>
<td>모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>3.62</td>
</tr>
</tbody>
</table>
</figure>
Image created using artificial intelligence via Midjourney.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Large Cap

Mid Cap

Broad U.S. Equity ETFs

DXCM

S&P 500과 나스닥 100은 월가의 불안감이 사라져 8일 연속 상승: 월요일의 상승 주식

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>가이드와이어 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 <a href="https://www.benzinga.com//node/39183330" target="_blank" rel="noreferrer noopener">상향 조정했다</a>.</li>
<li>GFL 인바이런먼털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)의 주가는 회사가 2건의 인수 제안을 검토하기 위해 금융 자문가를 고용했다는 내용의 보도 이후 11.62% 상승했다.</li>
<li>크라우드스트라이크 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)의 주가는 회사가 강력한 지침을 발표한 후 9.36% 상승했다. 몇몇 분석가들은 예측을 <a href="https://www.benzinga.com//node/39182501" target="_blank" rel="noreferrer noopener">재조정</a>했다.</li>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주가가 지난 주 9.26% 상승했습니다. 이는 지난 주에 <a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">엔비디아</a>의 주가가 상승하며 사상 최고치에 가까운 수준에서 거래를 마쳤다는 소식에 이어 일어난 일다.</li>
<li>일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)의 주가가 9.16% 상승했습니다. 이사회는 2024년 6월 12일경에 시작될 것으로 예상되는 &#8216;발행 시점&#8217; 거래인 그레일(GRAIL)의 분사를 승인했다.</li>
<li>사이아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>)의 주식은 8.31% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/39155966" target="_blank" rel="noreferrer noopener">4월 근무일당</a> LTL 배송량이 18% 증가했다고 보고한 이후 일어났다.</li>
<li>엘라스틱 N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)의 주가가 7.65% 상승했습니다.</li>
<li>코히런트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>)의 주가는 6월 3일부터 이사회가 짐 앤더슨(Jim Anderson)을 <a href="https://www.benzinga.com/pressreleases/24/06/g39134653/coherent-appoints-jim-anderson-as-chief-executive-officer" target="_blank" rel="noopener">새로운 CEO</a>로 임명하면서 지난주 7.12% 상승했다.</li>
<li>팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)의 주가가 7.02% 상승했다. 이는 회사의 <a href="https://www.benzinga.com//node/39223353" target="_blank" rel="noreferrer noopener">AIPCon 이벤트</a>가 주식 가격에 영향을 미쳤기 때문다.</li>
<li>보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): 2018년과 2019년에 346명의 사망자를 낸 치명적인 충돌 사고에 대해 <a href="https://www.benzinga.com//node/39142764" target="_blank" rel="noopener">경영진이 형사 고발을 당할 가능성이 낮다</a>는 로이터 통신의 보도 이후 지난주 주가는 6.82% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 더 읽어보기: <a href="https://www.benzinga.com/news/24/06/39243316/gamestop-and-nio-were-among-the-11-biggest-large-cap-losers-last-week-june-1-june-7-are-these-in-you">게임스탑과 니오는 지난주 최악의 성과를 보인 11개의 대형주 중 일부 (6월 1일-6월 7일)</a>

Comments

Illumina

뉴스

에 대한 최신 뉴스 Illumina (NASDAQ:ILMN) 주식

화요일, 1월 14, 2025

일요일, 1월 12, 2025

화요일, 12월 24, 2024

금요일, 12월 20, 2024

화요일, 12월 17, 2024

토요일, 12월 14, 2024

월요일, 8월 19, 2024

일요일, 6월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌